The <scp>pan‐JAK</scp> inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16‐week randomized phase <scp>IIb</scp> trial*
The <scp>pan‐JAK</scp> inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16‐week randomized phase <scp>IIb</scp> trial* is a paper indexed in ScholarIQ from OpenAlex.
How many citations does The <scp>pan‐JAK</scp> inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16‐week randomized phase <scp>IIb</scp> trial* have?
The <scp>pan‐JAK</scp> inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16‐week randomized phase <scp>IIb</scp> trial* has 89 citations in the OpenAlex counts ScholarIQ stores.
When was The <scp>pan‐JAK</scp> inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16‐week randomized phase <scp>IIb</scp> trial* published?
The <scp>pan‐JAK</scp> inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16‐week randomized phase <scp>IIb</scp> trial* has 2022 year in the ScholarIQ index.
What is the open-access status of The <scp>pan‐JAK</scp> inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16‐week randomized phase <scp>IIb</scp> trial*?
The <scp>pan‐JAK</scp> inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16‐week randomized phase <scp>IIb</scp> trial* has hybrid oa status in the ScholarIQ index.
What is the DOI of The <scp>pan‐JAK</scp> inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16‐week randomized phase <scp>IIb</scp> trial*?
The DOI for The <scp>pan‐JAK</scp> inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16‐week randomized phase <scp>IIb</scp> trial* is on the source record.
What is the PMID of The <scp>pan‐JAK</scp> inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16‐week randomized phase <scp>IIb</scp> trial*?
The PMID for The <scp>pan‐JAK</scp> inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16‐week randomized phase <scp>IIb</scp> trial* is on the source record.
What is the OpenAlex record for The <scp>pan‐JAK</scp> inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16‐week randomized phase <scp>IIb</scp> trial*?
The OpenAlex for The <scp>pan‐JAK</scp> inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16‐week randomized phase <scp>IIb</scp> trial* is on the source record.